Principal Investigator: Fahimeh Ramezani Tehrani

Professor of Obstetrics, Gynaecology and Reproductive Health -Shahid Beheshti University of Medical Sciences- Director, Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences

Part Cohort

There is a moment in the life of any aspiring astronomer that it is time to buy that first telescope. It’s exciting to think about setting up your own viewing station.

Staffs


Subclinical Thyroid Dysfunctions and Pregnancy and Neonatal Outcomes (STYPRN)


More

News


Subclinical Thyroid Dysfunctions and Pregnancy and Neonatal Outcomes (STYPRN)


More

Publications


Subclinical Thyroid Dysfunctions and Pregnancy and Neonatal Outcomes (STYPRN)


More

Gallery


Subclinical Thyroid Dysfunctions and Pregnancy and Neonatal Outcomes (STYPRN)


More

Approval date:

June 11, 2013

Starting date:

June 11, 2013

 

Goals:


To identify the prevalence of subclinical thyroid dysfunction in pregnancy (phase 1) and assessment of the effect of Levothyroxine on pregnancy outcomes of pregnant women with subclinical thyroid dysfunction

Study population:


Pregnant women attending prenatal clinics under coverage of Shahid Beheshti University of Medical Sciences, Tehran, Iran

Sampling method and sample size:


First phase: Stratified, multistage probability cluster sampling method (n=3000). Second phase: Randomized clinical trial; number of sample for each group=200

Data Collection:


Interview, questionnaire, physical exam, collecting of blood and urine samples for assessment of serum levels of TSH, T4, T3uptake and TPOab and urinary iodine

Follow up Methods:


- Active fallow-up every 3 months to repeat all measurements.
- Active follow up delivery and/or hospitalized events.

Main Exposures:


Serum levels of TSH, T4, T3 Uptake, TPO Ab and urinary Iodine

 

Outcomes:


Pregnancy and newborn outcomes

Related links

Last Newsletter

Lorem ipsum


More

Lorem ipsum


More